Monthly Archives: October 2017

Drugging The Undruggable: Kymera’s Targeted Protein Degradation
October 30, 2017

The term “undruggable” has entered common industry vernacular over the past two decades to describe biologic targets that couldn’t be addressed via narrow conventional pharmacologies involving catalytic-site inhibitors and antibodies. The “druggable genome” historically included intracellular catalytic proteins, (e.g., enzymes

Leave a comment

To IPO or Not To IPO
October 25, 2017

This blog was written by Sam Truex, former CBO of Padlock and Synlogics, and current Atlas EIR, as part of the From the Trenches feature of LifeSciVC. Funding for biotech companies has been abundant this year. As covered the first


Transplant Tailwinds and Momentum
October 16, 2017

This blog was written by Jason Gardner, CEO and co-founder of Magenta Therapeutics, as part of the From The Trenches feature of LifeSciVC.            There’s a proverb that goes like this, “If you want to go

Leave a comment

Launching Science2Startup: Connecting Academics With Venture
October 6, 2017

We’re excited to announce the launch of Science2Startup, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities. This event is in many ways a relaunch of the successful URES (University Research

Leave a comment

Nimbus Therapeutics Reaches Summit For Deal With Celgene
October 3, 2017

Today Nimbus and Celgene announced a significant partnership focused on autoimmune and inflammatory diseases. The alliance includes two pre-clinical autoimmune-focused programs in various stages of drug discovery. The most advanced program is a highly selective inhibitor of Tyk2, an immunokinase

Leave a comment

VC-Backed Biotech Financings: Boom Or Bubble?
October 2, 2017

Private biotech funding numbers are in for the third quarter and on an absolute capital basis they are huge: $3.6B flowed into private biotechs, the largest quarter of VC-funding into biopharma ever in the history of our industry, according to

Leave a comment